Current Report Filing (8-k)
May 29 2020 - 8:17AM
Edgar (US Regulatory)
false000004907100000490712020-05-292020-05-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
|
FORM 8-K
|
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date
of earliest event reported): May 29, 2020 (May 29, 2020)
|
Humana Inc.
(Exact Name of Registrant as Specified in Charter)
|
500 W. Main Street,
Louisville, Kentucky 40202
(Address of Principal Executive Offices, and Zip Code)
(502) 580-1000
Registrant’s Telephone Number, Including Area Code
(Former Name or Former Address, if
Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors at
various times between June 1, 2020 and June 30, 2020. During the meetings, while continuing to acknowledge the inherent uncertainty surrounding the ongoing 2019 coronavirus (“COVID-19”) crisis and reiterating that it has withdrawn its additional
detailed financial guidance given the likelihood of significant variability of results by financial statement line item (and related ratios), the Company intends to reaffirm its guidance range of $16.04 to $16.54 in diluted earnings per common
share (“EPS”), or $18.25 to $18.75 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2020 (“FY 2020”). This guidance is consistent with the guidance issued in Humana’s press release dated April
29, 2020. The date and time of presentations to investors are available via the Investor Relations calendar of events on Humana’s website at humana.com.
The Company has included Adjusted EPS in this current report, a financial measure that is not in
accordance with Generally Accepted Accounting Principles (“GAAP”). Management believes that this measure, when presented in conjunction with the comparable measure of GAAP EPS, is useful to both management and its investors in analyzing the
Company’s ongoing business and operating performance. Consequently, management uses Adjusted EPS as an indicator of the Company’s business performance, as well as for operational planning and decision making purposes. Adjusted EPS should be
considered in addition to, but not as a substitute for, or superior to, GAAP EPS. A reconciliation of GAAP EPS to Adjusted EPS follows:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated: May 29, 2020
Humana (NYSE:HUM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Humana (NYSE:HUM)
Historical Stock Chart
From Sep 2023 to Sep 2024